MMedication Read More Large GLP-1 Drug Review Takes Closer Look at Risks, RewardsApril 1, 2026 Moderate- to high-quality evidence from an umbrella review on non-cardiometabolic outcomes reinforced links between GLP-1 therapies and risks…